Driving long-term growth – Annual Report and Accounts 2024
Key highlights include:
- Across its three programmes, British Patient Capital manages assets with a total value of £3,125m.
- In 2023/24, British Patient Capital made 10 new fund commitments and 5 new co-investments from the core programme, and 10 direct investments via Future Fund: Breakthrough, totalling £66m.
- Investments since inception totalled £2.287m across 80 fund commitments, 10 co-investments, and 18 Future Fund: Breakthrough deals.
- The funds in which British Patient Capital has invested have raised a further £13.4bn from third party investors.
- Analysis undertaken by the British Business Bank shows that since British Patient Capital was established, the UK has narrowed its overall VC investment gap with the US.
Investing in tomorrow – Annual Report and Accounts 2023
Key highlights include:
- Across its three programmes, British Patient Capital manages assets with a total value of £3,075m.
- Investments since inception totalled £1,898m across 70 fund commitments, six co-investments, and 16 Future Fund: Breakthrough deals.
- Total commitments, including capital from other institutional investors, now total £13bn.
- In 2022/23, we made eight new fund commitments and two co-investments from the core programme, and 10 direct investments via Future Fund: Breakthrough.
- Announced the first investment through our Life Sciences Investment Programme.
Investing in Innovation – Annual Report and Accounts 2022
Key highlights include:
- Across its three programmes, British Patient Capital now manages assets with a total value of £3,075 million.
- Investments since inception totalled £1,635 million across 61 fund commitments, four co-investments and five Future Fund: Breakthrough deals.
- Total commitments, including capital from other institutional investors, now total more than £10.7 billion.
- In 2021/22, we made 10 new fund commitments and two co-investments from the core programme, with a total value of £341 million.
- The total portfolio Internal Rate of Return since inception for the core programme was 32.9% to end of March 2022, compared to 25.3% in March 2021.
- The portfolio TVPI of the core programme was 1.80x, up from 1.51x the previous year.
Accelerating Innovation – Annual report 2021
While the impact of Covid-19 led to profound difficulties for many individuals and businesses, it also highlighted the importance of innovation and the value of innovative companies to society and the economy.
Fuelling innovation, powering growth – Annual report 2020
British Patient Capital’s total commitments reach over £1 billion.
Investing in ambition – Annual report 2019
British Patient Capital establishes itself as a major player in UK venture and venture growth markets: Investing in 12 funds with £334 million of new commitments in its first year